Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092598 | 0.93 | NPC1 (0.45) | NPC1RAB9AMETNR3C1KDM4E | |
| SCHEMBL2091601 | 0.90 | TACR3 (0.39) | NPC1RAB9AMETNR3C1TACR3 | |
| SCHEMBL2095287 | 0.89 | TACR3 (0.40) | NPC1RAB9ANR3C1TACR3STIM1 | |
| SCHEMBL13324347 | 0.88 | RAB9A (0.47) | NPC1RAB9AF10 | |
| SCHEMBL2092551 | 0.87 | MAPT (0.43) | NPC1RAB9ANR3C1KDM4ETACR3 | |
| SCHEMBL2091845 | 0.86 | NPC1 (0.44) | NPC1RAB9ATLR8KDM4ETACR3 | |
| SCHEMBL2092726 | 0.86 | STIM1 (0.56) | METNR3C1TACR3STIM1ORAI1 | |
| SCHEMBL2093586 | 0.86 | MAPT (0.50) | NPC1RAB9AMAPK1LMNA | |
| SCHEMBL2090228 | 0.86 | RAB9A (0.40) | NPC1RAB9AKDM4EKDRTEK | |
| SCHEMBL2093470 | 0.86 | NPC1 (0.45) | NPC1RAB9AABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | claimed |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | claimed |
| US-7709518-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-04 | — | — | US | claimed |
| EP-1809294-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | claimed |
| EP-1809294-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006034402-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICAL CORP. (US) | 2006-03-30 | — | — | WO | claimed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1809294-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006034402-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICAL CORP. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | NPC1 142/4885RAB9A 1725/4885CLK1 3014/4885 |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | CXCR2, CXCL8, CCR9 | NPC1 142/4885RAB9A 1725/4885CLK1 3014/4885 |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | NPC1 142/4885RAB9A 1725/4885CLK1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.